#USA #Washington #Vanda Pharmaceuticals #Fanapt #Bysanti

Vanda Pharmaceuticals Q1 2025 Financial Overview

Vanda Pharmaceuticals Inc. has recently disclosed its financial and operational performance for the first quarter ending March 31, 2025. The company has reported remarkable growth in its product sales and significant advancements in its drug development pipeline, signaling a robust phase of expansion and innovation.

Strong Prescription Growth

The first quarter of 2025 was marked by an impressive increase in prescriptions for Vanda's leading product, Fanapt® (iloperidone), which soared by 14% compared to the first quarter of 2024. This growth is noteworthy as it reflects a substantial uptick in new patients starting treatment with Fanapt, with new brand prescriptions rising nearly threefold in the same time frame. By the end of April 2025, weekly prescriptions for Fanapt surpassed 2,000, positioning it as one of the fastest-growing atypical antipsychotics in the market.

Financial Highlights

In terms of financial performance, Vanda reported total net product sales of $50.0 million for the first quarter of 2025, marking a 5% increase from the $47.5 million reported in the same quarter the previous year. Of this, Fanapt® alone generated $23.5 million, reflecting a 14% growth compared to $20.6 million in Q1 2024. Other products also contributed positively, with HETLIOZ® bringing in $20.9 million and PONVORY® at $5.6 million, although PONVORY saw an 18% decrease from the prior year.

Despite these gains, Vanda incurred a net loss of $29.5 million in Q1 2025, which is a major increase from the $4.1 million loss recorded in Q1 2024. This elevated loss primarily stems from expenses related to a $15.0 million payment tied to a global license agreement for imsidolimab, alongside increased commercial activities.

Key Operational Developments

Vanda's operational highlights are promising, particularly concerning its expanding drug pipeline. The New Drug Application (NDA) for its product Bysanti™ (milsaperidone), aimed at treating bipolar I disorder and schizophrenia, has been accepted for filing by the FDA. The expected target action date for this application is February 21, 2026.

Moreover, the NDA for Tradipitant, which addresses motion sickness, has also been accepted, with a projected action date of December 30, 2025. Vanda's ambitious plans include submitting a Biologics License Application (BLA) for imsidolimab in the treatment of generalized pustular psoriasis within 2025.

Investing in Future Growth

Vanda is actively broadening its sales force, now numbering around 400 employees, a new high for the company, as part of its strategy to enhance market presence and customer engagement. The leadership team has made significant investments in both expanding product awareness and increasing prescription rates for existing offerings, particularly for Fanapt® and PONVORY®.

The company's optimism is further backed by its 2025 guidance, estimating total revenues will range from $210 million to $250 million, while year-end cash reserves are anticipated to be between $280 million and $320 million. This proactive financial management reflects Vanda's commitment to sustained growth and innovation in the biopharmaceutical sector.

Concluding Remarks

Vanda Pharmaceuticals stands poised for continued growth, driven by the successful launches of Fanapt® and PONVORY®, alongside a promising portfolio of new drugs in the pipeline. As the company forges ahead into 2025, its strategic focus on expanding market share, innovating treatment options, and bolstering its workforce serves as a solid foundation for future successes.